munKNEE.com Your Key to Making Money
An original article by Lorimer Wilson, Founder and Managing Editor of munKNEE.com – a site for sore eyes and inquisitive minds and your KEY to making money – which was first posted on TalkMarkets.com under the title “Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May” with 980 pageviews to date.
An Introduction
This article highlights the 10 clinical-stage AI-powered (designated with *) and psychedelic compound-based (designated with **) small cap ($400M to $2.0B) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances the first of May week, in descending order, and YTD and their areas of focus along with the latest news, analyses and commentary where available.
- **Mind Medicine (MNMD): UP 17.4% during the first week of May; UP 173.2% YTD
- *Exscientia (EXAI): UP 15.9% during the first week of May; DOWN 27.1% YTD
- reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Latest news, commentary and/or analysis: None
- **GH Research (GHRS): UP 11.1% during the first week of May; UP 101.4% YTD
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- *Absci Corporation (ABSI): UP 10.9% during the first week of May; UP 21.0% YTD
- focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Latest news, commentary and/or analysis: None
- *Relay Therapeutics (RLAY): UP 10.5% during the first week of May; DOWN 36.1% YTD
- specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detects and characterizes interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Latest news, commentary and/or analysis:
- *Recursion Pharmaceuticals (RXRX): UP 8.8% during the first week of May; DOWN 10.3% YTD
- has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Latest news, commentary and/or analysis:
- **Compass Pathways (CMPS): UP 7.4% during the first week of May; DOWN 7.5% YTD
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest news, commentary and/or analysis:
- *AbCellera Biologics (ABCL): UP 7.2% during the first week of May; DOWN 29.4% YTD
- develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- Latest news, commentary and/or analysis:
- **atai Life Sciences (ATAI): UP 6.2% during the first week of May; UP 45.4% YTD
- *Schrödinger (SDGR): DOWN 1.2% during the first week of May; DOWN 33.9% YTD
- specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Latest news, commentary and/or analysis:
Summary
On average, the above 10 stocks were UP 7.4% during the first week of May but are now DOWN 7.6% YTD.